Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Protest Trial
NCT06422273Phase 3Enrolling by invitation
- Sponsor
- Corewell Health
- Start
- Apr 2024
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of tranexamic acid in hemorrhage (2 arms), sponsored by Corewell Health. Primary endpoint: Bleeding Risk up to 1 hour. Started Apr 2024; status: enrolling by invitation.
02
Drugs
tranexamic acid
03
Conditions
hemorrhage
Beyond the preview
Go deeper on NCT06422273.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06422273.